–by Marie Jung On August 24th, 2016, the San Diego community and the rest of the world lost one of the brightest minds to have graced the surface of the earth. Robert Tsien, Ph.D and Nobel Laureate opened up countless doors in the clinical research and medical fields with his Read more
–by Marie Jung The popularization of science may not be new, but there seems to be a growing trend towards improving scientific literacy among the general public. The revamping of Carl Sagan’s beloved Cosmos series really indicates the renewed interest in the natural world. The most prominent changes, however, take Read more
Over 130 scientists, lawyers, entrepreneurs, and government officials from five continents gathered at Harvard this week for an “exploratory” meeting to discuss the topic of creating genomes from scratch — including, but not limited to, those of humans, said George Church, Harvard geneticist and co-organizer of the meeting. (STAT)
Noah Craft, M.D., Ph.D., CEO and Co-Founder of Science 37, will be speaking in San Diego on May 9 at a program jointly organized by San Diego Clinical Research Network and San Diego Regulatory Affairs Network, Accelerating Clinical Trials Using Mobile Technologies: Current Trends and Regulatory Update. The program will be Monday May 9, 5:15-8:00 Read more
…We found that the average present values of lifetime net economic returns were positive and reached a peak with the 1995–99 and 2000–04 new drug cohorts. However, returns have fallen sharply since then, with those for the 2005–09 cohort being very slightly negative and, on average, failing to recoup research and development and other costs.
Editas Medicine filed paperwork this morning for a $100 million initial public offering (IPO). The Cambridge, Massachusetts-based startup would become the first publicly-traded company specializing in gene editing, according to Bloomberg Business.
The clinical trials industry has undergone quite a bit of change in 2015, and may arguably be deemed the year of the ramping of clinical trial innovation.
A technique called optogenetics has transformed neuroscience during the past 10 years by allowing researchers to turn specific neurons on and off in experimental animals.
The US Food and Drug Administration (FDA) broke new ground last week when it authorized the world’s first human clinical trial for an in vivo genome editing application. The investigational new drug (IND) application approval for California-based Sangamo, which is the first and only company to put a gene editing therapy into clinical trials, allows the company to begin conducting in 2016 a Phase 1/2 open-label, dose-escalation study in up to nine male adults with severe hemophilia B. (Regulatory Focus, Regulatory Affairs Professionals Society)